Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model (Q40494911)

21 September 2017

title

Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model (English)

1 reference

21 September 2017

author

Cornelis J. M. Melief

11

object named as

Cornelis J M Melief

1 reference

21 September 2017

Sjoerd H van der Burg

13

object named as

Sjoerd H van der Burg

1 reference

21 September 2017

4

Kees L M C Franken

1 reference

21 September 2017

8

Hermen S Overkleeft

1 reference

21 September 2017

Marij J P Welters

1

1 reference

21 September 2017

Dmitri V Filippov

2

1 reference

21 September 2017

Susan J F van den Eeden

3

1 reference

21 September 2017

Jan Nouta

5

1 reference

21 September 2017

A Rob P M Valentijn

6

1 reference

21 September 2017

Gijs A van der Marel

7

1 reference

21 September 2017

Grayson Lipford

9

1 reference

21 September 2017

Rienk Offringa

10

1 reference

21 September 2017

Jacques H van Boom

12

1 reference

21 September 2017

Jan Wouter Drijfhout

14

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

23

1 reference

21 September 2017

issue

3

1 reference

21 September 2017

page(s)

305-311

1 reference

Strategies for immunotherapy of cancer

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Design and evaluation of antigen-specific vaccination strategies against cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Occurrence and Minimization of Cysteine Racemization during Stepwise Solid-Phase Peptide Synthesis1,2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Solid Phase Synthesis of Peptide C-Terminal Thioesters by Fmoc/t-Bu Chemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Efficient semisynthesis of a tetraphosphorylated analogue of the Type I TGFbeta receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Methods and strategies of peptide ligation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Synthesis of native proteins by chemical ligation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Generation of CD8( ) T cell memory in response to low, high, and excessive levels of epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Total chemical synthesis and electrophysiological characterization of mechanosensitive channels from Escherichia coli and Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

The first semi-synthetic serine protease made by native chemical ligation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.008

10.1016/J.VACCINE.2004.06.008

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference